$NPHC "Based on our pre-clinical and open-label cl

$NPHC "Based on our pre-clinical and open-label clinical studies, we believe that RPI-78M has the ability to successfully navigate the FDA approval process," commented Dale Vander Putten, PhD, Nutra Pharma's Chief Scientific Officer. "We believe that a recombinant product will ultimately provide these kids with the best possible drug. We are now working with the BSF to scale up drug manufacturing in preparation for the upcoming Phase II clinical trials," he concluded.

https://finance.yahoo.com/news/nutra-pharma-a...00318.html